key: cord-0833926-3ejpe0k9
authors: Di Lernia, V.; Goldust, M.; Feliciani, C.
title: Covid‐19 infection in psoriasis patients treated with cyclosporin
date: 2020-06-01
journal: Dermatol Ther
DOI: 10.1111/dth.13739
sha: 7fad0f58ac4f5b97468c262b744a329ff0610d6c
doc_id: 833926
cord_uid: 3ejpe0k9

nan

Cyclosporin A (CsA) is a polypeptide immunosuppressant agent which suppresses T cell responses by preventing the transcription of genes encoding IL-2, which drives various lymphocyte subsets during differentiation, immune responses and homeostasis 4 . Due to its high efficacy and rapid onset of action, CsA has been widely used in dermatologic patients with psoriasis and atopic dermatitis, mostly in the short term. The primary molecular target of CsA is cyclophilin, a specific cytosolic binding protein, which is also required by many viruses for replication. Consequently, CsA is able to inhibit many viruses, among which influenza A virus, human immunodeficiency virus, hepatitis C virus, and coronaviruses 5-6 , including the two lifethreatening Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) 7 . Consequently, a possible beneficial effect has been speculated in patients taking CsA during COVID-19 outbreak [8] [9] .

A large number of individuals have been exposed to SARS-CoV2 so far, but currently, there are no data describing the benefits or risks of discontinuing CsA during the COVID-19 outbreak.

This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This is the first study evaluating the frequency and severity of COVID-19 in patients treated with CsA. This analysis has many limitations, since the number of patients with COVID-19

infection is too small to provide definitive conclusions. A particular susceptibility and severity of COVID-19 in patients treated with CsA was not observed. On the basis of our observation, there are not evidences that support a preventative discontinuation of CsA during COVID-19 outbreak in patients with psoriasis and atopic dermatitis. In addition to support advise and empowerment on activities to limit the risk of infection (hand hygiene, social distancing, use of protective devices), a telephone counselling may reassurance to the patients who spend at home the period of illness. Further observations or larger studies need to be done to confirm such approach.

This article is protected by copyright. All rights reserved.

COVID-19 Knowledge Prevents Biologics Discontinuation: Data From an Italian Multi-Center Survey During RED-ZONE Declaration

COVID-19 and Psoriasis: Is It Time to Limit Treatment With Immunosuppressants? A Call for Action

Biologics for psoriasis during COVID-19 outbreak

The role of interleukin-2 during homeostasis and activation of the immune system

Suppression of Coronavirus Replication by Cyclophilin Inhibitors. Viruses

Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity?

Cyclophilins and cyclophilin inhibitors in nidovirus replication

Antipsoriatic treatments during COVID-19 outbreak

Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern